Alnylam Pharma ( (ALNY) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alnylam Pharmaceuticals shares moved sharply after the company reported strong Phase 3 results from its HELIOS-B trial of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy. The study showed a statistically significant 28% to 33% reduction in the combined risk of death and repeat cardiovascular events, a key benchmark for heart disease drugs.
Analysts see the data as a major step toward potential regulatory approval and a shot at the lucrative rare heart disease market, which could reshape Alnylam’s long-term revenue outlook. These upbeat expectations are now being quickly priced into the stock as investors reassess the company’s growth prospects.
More about Alnylam Pharma
YTD Price Performance: -19.00%
Average Trading Volume: 1,312,888
Technical Sentiment Signal: Hold
Current Market Cap: $42.72B
For further insights into ALNY stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.